Docoh
Loading...

GSK Glaxosmithkline

Filed: 20 Feb 20, 9:41am
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
 
 
For the month of February 2020
 
Commission File Number 001-15170
 
 
GlaxoSmithKline plc
(Translation of registrant's name into English)
 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
 
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
 
 
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
 
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
 
 
GlaxoSmithKline plc (the 'Company')
 Transaction notification
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMs E Walmsley
b)Position/statusChief Executive Officer
c)Initial notification/amendmentInitial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)Nature of the transactionThe exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £0.0037,221 (Deferred) 
 £0.0024,815 (Matching) 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
62,036
£0.00
e)Date of the transaction2020-02-17
f)Place of the transaction
N/A
 
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMs E Walmsley
b)Position/statusChief Executive Officer
c)Initial notification/amendmentInitial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £16.61417,523 (Deferred) 
 £16.61411,680 (Matching) 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
29,203
£16.614
e)Date of the transaction2020-02-17
f)Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr R Connor
b)Position/statusPresident, Global Vaccines
c)Initial notification/amendmentInitial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)Nature of the transactionThe exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)Price(s) and volume(s) Price(s)Volume(s) 
��£0.0019,375 (Deferred) 
 £0.0012,917 (Matching) 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
32,292
£0.00                                                                              
e)Date of the transaction2020-02-17
f)Place of the transaction
N/A
 
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr R Connor
b)Position/statusPresident, Global Vaccines
c)Initial notification/amendmentInitial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £16.7149,120 (Deferred) 
 £16.7146,081 (Matching) 
    
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
15,201
£16.714                                                                             
e)Date of the transaction2020-02-17
f)Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr N Hirons
b)Position/statusSVP, Global Ethics and Compliance
c)Initial notification/amendmentInitial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)Nature of the transactionThe exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £0.0012,243 (Deferred) 
 £0.008,163 (Matching) 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
20,406
£0.00                                                                         
e)Date of the transaction2020-02-17
f)Place of the transaction
N/A
 
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr N Hirons
b)Position/statusSVP, Global Ethics and Compliance
c)Initial notification/amendmentInitial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £16.6785,770 (Deferred) 
 £16.6783,846 (Matching) 
    
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
9,616
£16.678                                                                
e)Date of the transaction2020-02-17
f)Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr B McNamara
b)Position/statusCEO, GSK Consumer Healthcare
c)Initial notification/amendmentInitial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
American Depositary Shares ('ADSs')
 
ISIN: US37733W1053
b)Nature of the transaction
The sale of ADSs to meet tax liabilities on the vesting of awards under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 $43.5443,467 (Deferred) 
 $43.5442,423 (Matching) 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
5,890
$43.544                                                                                      
e)Date of the transaction2020-02-18
f)Place of the transaction
New York Stock Exchange (XNYS)
 
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr D Redfern
b)Position/statusChief Strategy Officer
c)Initial notification/amendmentInitial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)Nature of the transactionThe exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £0.0015,407 (Deferred) 
 £0.0010,273 (Matching) 
    
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
25,680
£0.00                                          
e)Date of the transaction2020-02-17
f)Place of the transaction
N/A
 
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr D Redfern
b)Position/statusChief Strategy Officer
c)Initial notification/amendmentInitial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £16.6297,261 (Deferred) 
 £16.6294,840 (Matching) 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
12,101
£16.629                                         
e)Date of the transaction2020-02-17
f)Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr P Thomson
b)Position/statusPresident, Global Affairs
c)Initial notification/amendmentInitial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)Nature of the transactionThe exercise of nil-cost options over Ordinary Shares granted on 15 February 2017 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)Price(s) and volume(s) Price(s)Volume(s) 
 £0.007,302 (Deferred) 
 £0.004,869 (Matching) 
    
d)
Aggregated information
 
 
 
Aggregated volume
Price
 
12,171
£0.00                                                                                  
e)Date of the transaction2020-02-17
f)Place of the transaction
N/A
 
 
 
 
1.Details of PDMR/person closely associated with them ('PCA')
a)NameMr P Thomson
b)Position/statusPresident, Global Affairs
c)Initial notification/amendmentInitial notification
2.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameGlaxoSmithKline plc
b)LEI5493000HZTVUYLO1D793
3.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882
b)Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on the exercise of nil-cost options over Ordinary Shares under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
 
c)Price(s) and volume(s) Price(s)Volume(s) 
 £16.6233,442 (Deferred) 
 £16.6232,294 (Matching) 
    
d)
Aggregated information
 
N/A (single transaction)
 
Aggregated volume
Price
 
5,736
£16.623                                                                           
e)Date of the transaction2020-02-17
f)Place of the transaction
London Stock Exchange (XLON)
 
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 GlaxoSmithKline plc
 (Registrant)
  
Date: February 20, 2020 
  
 
By:/s/ VICTORIA WHYTE
--------------------------
  
 Victoria Whyte
 Authorised Signatory for and on
 behalf of GlaxoSmithKline plc